Keensight Capital to Acquire a Majority Stake in Leading European CRO and CDMO, Symeres, from Gilde Healthcare Private Equity
5/25, 9:00 AM (Source: GlobeNewswire)
PARIS, May 25, 2021 (GLOBE NEWSWIRE)
Keensight Capital, one of the principal private equity managers dedicated to pan-European Growth Buyout investments, has reached an agreement to invest alongside management in Symeres, a leading European drug discovery Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO). According to the terms of the agreement, Keensight Capital will acquire a majority stake in Symeres from the Gilde Healthcare Private Equity fund, a leading European specialist healthcare investor.
Symeres is one of the largest European small molecule CRO & CDMOs, providing R&D services from preclinical drug discovery to Phase I and II clinical stage drug development and manufacturing to major pharmaceutical and bi